US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Xtrackers Nifty 500 India ETF

23.07

+0.07000.30%

Post-market: 23.120.0550+0.24%16:10 EDT

Volume:2K

Turnover:56.63K

Market Cap:4.61M

PE:- -

High:23.28

Open:23.00

Low:23.00

Close:23.00

52wk High:27.40

52wk Low:20.52

Shares:200.00K

Float Shares:200.00K

Volume Ratio:15.02

T/O Rate:1.23%

Dividend:0.08

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Shanghai Henlius Biotech's Cancer Drug Combination Trial Gets IND Approval

MT Newswires Live

Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

Shandong Boan Biotechnology's Cancer Drug Candidate Gets IND Acceptance; Shares Down 5%

MT Newswires Live

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA

MT Newswires Live

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

ASCLETIS-B Submits Two IND Applications to US FDA for Obesity Treatments: Monthly Peptide Amylin Receptor Agonist ASC36 and ASC36_35 Combination Monthly Injection

India's Stock Market Emerges as a Defensive Haven Amid Global AI Turbulence

India's Stock Market Emerges as a Global Safe Haven Amid AI-Driven Volatility

India's Stock Market Emerges as a Defensive Haven Amid Global AI Turbulence

India Ratings assigns and affirms IND BBB+ / A2 ratings to Foods & Inns bank facilities

Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance

Benzinga_recent_news

Edding Genor Receives NMPA Approval for Phase Ib/II Clinical Trial of GB268

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101

Gain Therapeutics receives FDA clearance of GT-02287 IND application

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IND/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":23.065,"timestamp":1787601600000,"preClose":22.995,"halted":0,"volume":2451,"hourTrading":{"tag":"盘后","latestPrice":23.12,"preClose":23.065,"latestTime":"16:10 EDT","volume":7,"amount":161.455,"timestamp":1787602204726,"change":0.055,"changeRate":0.002385,"amplitude":0},"delay":0,"changeRate":0.0030441400304414127,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"Closed","change":0.07,"latestTime":"08-24 16:00:00 EDT","open":23,"high":23.28,"low":23,"amount":56631,"amplitude":0.012177,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":22.995,"sharesOutstanding":200001,"nav":23.031,"aum":4606217.85,"dividendRate":0.003408,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":23.1,"preClose":22.995,"latestTime":"09:29 EDT","volume":206,"amount":4758.869860000001,"timestamp":1787578199043,"change":0.105,"changeRate":0.004566,"amplitude":0.004784},"postHourTrading":{"tag":"盘后","latestPrice":23.12,"preClose":23.065,"latestTime":"16:10 EDT","volume":7,"amount":161.455,"timestamp":1787602204726,"change":0.055,"changeRate":0.002385,"amplitude":0},"volumeRatio":15.018366},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IND\",,,,,undefined,":{"symbol":"IND","floatShares":200001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":15.018366,"shares":200001,"dividePrice":0.0786,"high":23.28,"amplitude":0.012177,"preClose":22.995,"low":23,"week52Low":20.515,"pbRate":"--","week52High":27.4,"institutionHeld":0,"latestPrice":23.065,"eps":0,"divideRate":0.003408,"volume":2451,"delay":0,"ttmEps":0,"open":23,"prevYearClose":24.78,"prevWeekClose":22.995,"prevMonthClose":22.885,"prevQuarterClose":22.88,"fiveDayClose":23.005,"twentyDayClose":22.495,"sixtyDayClose":22.475},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND\",params:#limit:5,,,undefined,":[{"date":"2026-06-18","symbol":"IND","amount":0.07775,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-18","defaultRemindTime":1781789400000,"name":"Xtrackers Nifty 500 India ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-18","currency":"USD","dateTimestamp":1781755200000,"payDate":"2026-06-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-18","recordDate":"2026-06-18","paymentDate":"2026-06-26","value":0.07775,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IND\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650518161","title":"Shanghai Henlius Biotech's Cancer Drug Combination Trial Gets IND Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2650518161","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650518161?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:12","pubTimestamp":1783678326,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696) said its investigational new drug application for a Phase I clinical trial of HLX37 in combination with chemotherapy or HLX43 has been approved by China's National ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000306685.HKD","HK0000320223.HKD","BK4585","XBI","HK0000306701.USD","BK4581","BK4588","02696","BK1161","IND","HK0000165453.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650922495","title":"Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application","url":"https://stock-news.laohu8.com/highlight/detail?id=2650922495","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650922495?lang=en_us&edition=fundamental","pubTime":"2026-07-09 21:16","pubTimestamp":1783602970,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that the FDA has cleared the company’s investigational new drug, or IND, application for QRX003 for the trea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-clearance-of-qrx003-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-announces-fda-clearance-of-qrx003-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","BK4588","BK4139","QNRX","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649996159","title":"UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649996159","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649996159?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:00","pubTimestamp":1783512000,"startTime":"0","endTime":"0","summary":"FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026UGN-501 is a different","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3324037/0/en/UroGen-Announces-FDA-Clearance-of-the-IND-for-UGN-501-an-Investigational-Next-Generation-Oncolytic-Virus-for-Non-Muscle-Invasive-Bladder-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","IND","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649996156","title":"Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2649996156","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649996156?lang=en_us&edition=fundamental","pubTime":"2026-07-08 20:00","pubTimestamp":1783512000,"startTime":"0","endTime":"0","summary":"-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD --  -- Prime Medicine owes no monetary dama","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3324031/0/en/Prime-Medicine-Announces-Positive-Resolution-to-Arbitration-with-Beam-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","CTA","IND","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649968198","title":"Shandong Boan Biotechnology's Cancer Drug Candidate Gets IND Acceptance; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649968198","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649968198?lang=en_us&edition=fundamental","pubTime":"2026-07-08 14:16","pubTimestamp":1783491408,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co (HKG:6955) said its investigational new drug application for BA1203 has been accepted by China's Center for Drug Evaluation of the National Medical Products Administrati","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06955","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987048","title":"Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987048","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987048?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:30","pubTimestamp":1783427400,"startTime":"0","endTime":"0","summary":"Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323198/0/en/Oragenics-Achieves-Full-Activation-of-Australian-Phase-IIa-Trial-Network-All-Three-Sites-Now-Enrolling.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IND","BK4139","LABU","BK4588","OGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649118606","title":"Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2649118606","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649118606?lang=en_us&edition=fundamental","pubTime":"2026-07-07 12:17","pubTimestamp":1783397876,"startTime":"0","endTime":"0","summary":"Celltrion  submitted an investigational new drug  amendment for a global Phase 3 trial of CT-P51, the biosimilar of its cancer drug Keytruda, to the U.S. Food & Drug Administration, according to a Monday filing with the Korea Exchange.The randomized, double-blind, active-controlled clinical trial will enroll 220 previously untreated patients who have metastatic non-squamous non-small cell lung cancer to compare the efficacy and safety of CT-P51 against the reference drug over a two-year treatment period, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK7095","IND.AU","BK4588","LABU","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649235026","title":"Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2649235026","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649235026?lang=en_us&edition=fundamental","pubTime":"2026-07-06 18:00","pubTimestamp":1783332000,"startTime":"0","endTime":"0","summary":"Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyImmuron is seeking a partner to support clinical development through regulatory approval and commercializationImmuron","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322259/37134/en/Immuron-Advances-IMM-529-Clostridioides-difficile-infection-Partnering-Strategy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SOC","BK4213","IMRN","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155756914","title":"ASCLETIS-B Submits Two IND Applications to US FDA for Obesity Treatments: Monthly Peptide Amylin Receptor Agonist ASC36 and ASC36_35 Combination Monthly Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1155756914","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155756914?lang=en_us&edition=fundamental","pubTime":"2026-07-06 08:10","pubTimestamp":1783296638,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) has announced it recently submitted two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA).The applications are for a next-generation,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01477","BK1161","BK4160","JDOC","BK4144","IND","BK1574","01672","BK4585","BK4588","BK4590","GIPR","GLP","LABU","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183558958","title":"India's Stock Market Emerges as a Defensive Haven Amid Global AI Turbulence","url":"https://stock-news.laohu8.com/highlight/detail?id=1183558958","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183558958?lang=en_us&edition=fundamental","pubTime":"2026-07-05 21:21","pubTimestamp":1783257672,"startTime":"0","endTime":"0","summary":"Global investors are reassessing the value of allocating funds to the Indian stock market. At a time when AI-driven trading continues to amplify volatility across global markets, India's market,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVEM","MFEM","XXCH","KEMX","XCNY","INCO","INDL","BCHI","BK4523","BK4588","DFAE","MEMX","AIPO","SPEM","IND","INDA","VTHR","EEMV","RWEM","PEMX","IMVP","SMIN","INDE","SCHE","EPI","XSOE","BK4550","BKF","AGIX","VEU","DEXC","XCEM","EQLT","BK4585","SEEM","EET","INDH","EEMA","NFTY","STXE","XC","INQQ","INDY","FLIN","MEM","QLVE","NDIA","SCIN","QEMM","HEEM","ASIA","CHAT","PIN","EMXC","IOPP","FEMR","BBEM","QTOC","BKEM","ARTY","GLIN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161120576","title":"India's Stock Market Emerges as a Global Safe Haven Amid AI-Driven Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=1161120576","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161120576?lang=en_us&edition=fundamental","pubTime":"2026-07-05 19:51","pubTimestamp":1783252276,"startTime":"0","endTime":"0","summary":"India's stock market, with its low correlation to the artificial intelligence theme, is becoming a hedging tool for risk diversification within emerging market portfolios, transforming its perceived...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLIN","BK4523","RWEM","XCNY","IOPP","BKF","PEMX","DEXC","SEEM","INCO","XCEM","MFEM","STXE","INDA","MEM","PIN","FLIN","SPEM","AIPO","EMXC","VTHR","SCHE","BBEM","BKEM","ASIA","AVEM","MEMX","NDIA","XXCH","INDL","AGIX","SCIN","NFTY","IMVP","CHAT","KEMX","DFAE","SMIN","QTOC","EEMV","BK4550","INQQ","INDE","XSOE","VEU","BCHI","EET","EQLT","XC","IND","INDY","INDH","BK4585","BK4588","QLVE","FEMR","EEMA","HEEM","QEMM","EPI","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138230472","title":"India's Stock Market Emerges as a Defensive Haven Amid Global AI Turbulence","url":"https://stock-news.laohu8.com/highlight/detail?id=1138230472","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138230472?lang=en_us&edition=fundamental","pubTime":"2026-07-05 18:03","pubTimestamp":1783245823,"startTime":"0","endTime":"0","summary":"Global investors are reassessing the value of allocating to Indian equities. At a time when artificial intelligence trading continues to amplify volatility across global markets, the Indian market,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEEM","IND","XSOE","QEMM","GLIN","MFEM","BBEM","BK4523","FLIN","DFAE","SEEM","SPEM","INDE","CHAT","SCIN","AVEM","MEMX","IMVP","QLVE","KEMX","XCNY","IOPP","VEU","AGIX","BKEM","AIPO","PEMX","VTHR","EEMA","INQQ","NDIA","BK4585","FEMR","BK4588","INDL","RWEM","STXE","BKF","QTOC","DEXC","EEMV","INDA","PIN","SCHE","BK4550","INDH","BCHI","ASIA","EMXC","ARTY","EET","INDY","EQLT","SMIN","XCEM","MEM","INCO","XXCH","NFTY","EPI","XC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648695926","title":"India Ratings assigns and affirms IND BBB+ / A2 ratings to Foods & Inns bank facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2648695926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648695926?lang=en_us&edition=fundamental","pubTime":"2026-07-03 21:03","pubTimestamp":1783083808,"startTime":"0","endTime":"0","summary":"The latest update is out from Foods & Inns Ltd. ( ($IN:FOODSIN) ). Foods & Inns Ltd. has announced that India Ratings & Research has reviewed and a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/india-ratings-assigns-and-affirms-ind-bbb-a2-ratings-to-foods-inns-bank-facilities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/india-ratings-assigns-and-affirms-ind-bbb-a2-ratings-to-foods-inns-bank-facilities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBB","IND","MNDmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648684703","title":"Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2648684703","media":"Benzinga_recent_news","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648684703?lang=en_us&edition=fundamental","pubTime":"2026-07-03 01:05","pubTimestamp":1783011900,"startTime":"0","endTime":"0","summary":"Abbisko and AstraZeneca will jointly develop a Phase 1/2 NSCLC therapy combining lumipodlin with Tagrisso after China's IND clearance.","market":"sh","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/07/02/Doctor-Hand-Point-Patient-Lung-X-ray-Fil.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/07/02/Doctor-Hand-Point-Patient-Lung-X-ray-Fil.jpg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/07/60253296/abbisko-astrazeneca-team-up-on-lung-cancer-drug-combo-after-china-trial-clearance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/07/60253296/abbisko-astrazeneca-team-up-on-lung-cancer-drug-combo-after-china-trial-clearance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4120","TISI","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100428930","title":"Edding Genor Receives NMPA Approval for Phase Ib/II Clinical Trial of GB268","url":"https://stock-news.laohu8.com/highlight/detail?id=1100428930","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100428930?lang=en_us&edition=fundamental","pubTime":"2026-07-02 22:35","pubTimestamp":1783002933,"startTime":"0","endTime":"0","summary":"Edding Genor (06998) has announced that its Investigational New Drug application for the Phase Ib/II clinical trial of GB268, a highly differentiated and innovative PD-1/CTLA-4/VEGF trispecific...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06998","BK1574","BK1583","IND","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648021135","title":"OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2648021135","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648021135?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:00","pubTimestamp":1782993600,"startTime":"0","endTime":"0","summary":"BOULDER, Colo., July  02, 2026  (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/02/3321271/0/en/OnKure-Therapeutics-to-Host-Virtual-KOL-Event-to-Discuss-PI3K%CE%B1-Inhibitor-Medicines-Selectivity-Matters-Pan-Mutant-Allosteric-Inhibition-Delivers-on-July-15-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KOL","HST","BK4134","MDCO","LENZ","BK4539","TSRI","BK4218","BK4585","BK4181","BK4007","BK4139","IND","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648546132","title":"NewcelX completes Type B Pre-IND meeting with FDA for NCEL-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2648546132","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648546132?lang=en_us&edition=fundamental","pubTime":"2026-07-01 21:35","pubTimestamp":1782912915,"startTime":"0","endTime":"0","summary":"NewcelX (NCEL) announced the completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration. The agency provided constructive ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/newcelx-completes-type-b-pre-ind-meeting-with-fda-for-ncel-101-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/newcelx-completes-type-b-pre-ind-meeting-with-fda-for-ncel-101-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4585","IND","BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647302913","title":"Gain Therapeutics receives FDA clearance of GT-02287 IND application","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302913","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647302913?lang=en_us&edition=fundamental","pubTime":"2026-06-30 04:20","pubTimestamp":1782764450,"startTime":"0","endTime":"0","summary":"Gain Therapeutics (GANX) announced that the FDA has authorized the company’s investigational new drug, or IND, application for GT-02287. The FDA’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gain-therapeutics-receives-fda-clearance-of-gt-02287-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gain-therapeutics-receives-fda-clearance-of-gt-02287-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GANX","GT","BK4119","BK4585","LABU","BK4588","IND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647472304","title":"DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2647472304","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647472304?lang=en_us&edition=fundamental","pubTime":"2026-06-30 04:00","pubTimestamp":1782763200,"startTime":"0","endTime":"0","summary":"Chtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/29/3319270/0/en/DBV-Technologies-Provides-BLA-Submission-Update-for-the-VIASKIN-Peanut-Patch-in-Children-Aged-4-through-7-Years-Working-Collaboratively-with-FDA-to-Optimize-Review-Process-in-Prepa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","BK4588","DBV","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647937940","title":"Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647937940","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647937940?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:01","pubTimestamp":1782734460,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., June  29, 2026  (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announce","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/29/3318916/36461/en/Voyager-s-Tau-Targeted-Gene-Therapy-VY1706-for-Alzheimer-s-Disease-to-Be-Featured-in-Developing-Topics-Poster-Presentation-at-AAIC-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","AAIC","BK4590","IND","BK4144","BK4132","AD","BK4110"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}